Healthcare > Pharmaceuticals & Biotechnology
•2438 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2438)
| Company | Market Cap | Price |
|---|---|---|
|
LNTH
Lantheus Holdings, Inc.
Directly produces radiopharmaceutical imaging agents and related therapies (e.g., PYLARIFY, DEFINITY) and maintains an expanding pipeline in this modality.
|
$4.53B |
$66.62
|
|
IEP
Icahn Enterprises L.P.
Pharma segment includes global drug development and commercialization activities (eg. Qsiva) typical of Large Cap Pharma companies.
|
$4.44B |
$7.75
+0.32%
|
|
AKRO
Akero Therapeutics, Inc.
EFX is a biologic drug with a specialized delivery formulation (pre-filled syringe/lyophilized product), placing it squarely in the Drug Delivery Platforms category.
|
$4.37B |
$54.67
+0.04%
|
|
SRRK
Scholar Rock Holding Corporation
Directly develops and markets monoclonal antibody therapeutics (apitegromab, SRK-439, SRK-181) across SMA, obesity/metabolic, and oncology.
|
$4.35B |
$45.23
-3.50%
|
|
CELC
Celcuity Inc.
Core asset gedatolisib targets oncology indications, placing Celcuity squarely in Biotech - Oncology.
|
$4.34B |
$102.12
-2.97%
|
|
WGS
GeneDx Holdings Corp.
Companion diagnostics partnerships leverage genomic data to identify patients for therapies.
|
$4.33B |
$150.72
-0.52%
|
|
BLTE
Belite Bio, Inc
Lead product Tinlarebant is an ophthalmic drug targeting retinal diseases (STGD1/GA).
|
$4.15B |
$142.61
+0.91%
|
|
VKTX
Viking Therapeutics, Inc.
VK2735 is a peptide-based dual GLP-1/GIP receptor agonist, the company's lead therapeutic.
|
$4.06B |
$36.15
-2.51%
|
|
LEGN
Legend Biotech Corporation
CARVYKTI is a CAR-T cell therapy and Legend Biotech's flagship product, representing its direct cell-therapy manufacturing and commercialization activity.
|
$4.04B |
$22.00
-1.46%
|
|
TERN
Terns Pharmaceuticals, Inc.
The company is advancing oral small-molecule therapeutics (TERN-701 and TERN-601) for cancer and obesity, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$3.94B |
$44.02
-2.19%
|
|
AMRX
Amneal Pharmaceuticals, Inc.
Main revenue driver is generic drugs in Affordable Medicines.
|
$3.91B |
$12.46
+2.05%
|
|
GPCR
Structure Therapeutics Inc.
Company focuses on developing oral small-molecule GPCR-targeted therapeutics, including lead GLP-1R agonist and other oral GPCR modulators.
|
$3.86B |
$64.79
-3.39%
|
|
ACLX
Arcellx, Inc.
Company's lead products are CAR-T cell therapies within oncology; direct product category is cell therapy.
|
$3.79B |
$68.39
-4.83%
|
|
LGND
Ligand Pharmaceuticals Incorporated
Captisol and NITRICIL are platform technologies Ligand licenses/sells to enable drug solubility and tunable dosing, constituting drug delivery platforms.
|
$3.78B |
$192.77
+1.70%
|
|
SWTX
SpringWorks Therapeutics, Inc.
SpringWorks specializes in oncology therapies using targeted small-molecule modalities (nirogacestat and mirdametinib).
|
$3.52B |
$46.99
|
|
CNTA
Centessa Pharmaceuticals plc
ORX750 is an orally administered, high-potency orexin receptor 2 (OX2R) agonist, fitting the 'Oral Small Molecule Therapeutics' category.
|
$3.51B |
$26.23
-1.08%
|
|
RARE
Ultragenyx Pharmaceutical Inc.
Ultragenyx is a rare-disease focused biotech company with approved therapies and a pipeline centered on ultra-rare diseases.
|
$3.49B |
$36.24
+0.04%
|
|
ARQT
Arcutis Biotherapeutics, Inc.
Arcutis' ZORYVE topical PDE4 inhibitor targets inflammatory dermatologic conditions, aligning with Immunology Therapeutics.
|
$3.47B |
$28.94
-0.28%
|
|
VCYT
Veracyte, Inc.
Tests function as companion diagnostics to identify patients most likely to benefit from specific therapies.
|
$3.42B |
$43.56
+1.68%
|
|
TARS
Tarsus Pharmaceuticals, Inc.
XDEMVY is an FDA-approved ophthalmic drug and core commercial product for Demodex blepharitis.
|
$3.40B |
$80.48
-1.07%
|
|
XENE
Xenon Pharmaceuticals Inc.
Xenon's lead asset XEN1101 is a selective Kv7 potassium channel opener, mapping to Ion Channel Modulators.
|
$3.36B |
$43.76
-0.69%
|
|
FOLD
Amicus Therapeutics, Inc.
Amicus Therapeutics’s marketed products address rare genetic diseases (Fabry and Pompe) and its pipeline includes a rare-kidney disease program (DMX-200 for FSGS), placing it in Biotech - Rare Diseases.
|
$3.35B |
$10.88
+3.13%
|
|
NAMS
NewAmsterdam Pharma Company N.V.
Lead asset obicetrapib is an oral, small-molecule therapeutic, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$3.27B |
$35.38
-5.01%
|
|
UUUU
Energy Fuels Inc.
Radium/radioisotope recovery plans for targeted alpha therapy isotopes (radiopharmaceuticals).
|
$3.23B |
$13.98
-4.02%
|
|
MIRM
Mirum Pharmaceuticals, Inc.
Core business includes liver disease therapeutics, with LIVMARLI and CTEXLI and acquired bile acid medications.
|
$3.22B |
$64.08
-1.42%
|
|
IRON
Disc Medicine, Inc.
Disc Medicine concentrates on rare hematologic diseases (e.g., EPP, Diamond-Blackfan anemia) by targeting iron and heme pathways, with a pipeline centered on rare-disease indications.
|
$3.20B |
$91.94
+0.10%
|
|
APLS
Apellis Pharmaceuticals, Inc.
SYFOVRE is an ophthalmic drug (intravitreal) approved for geographic atrophy, representing a direct product Apellis sells.
|
$3.19B |
$24.55
-2.68%
|
|
VERA
Vera Therapeutics, Inc.
Atacicept is a biologic therapeutic (dual BAFF/APRIL inhibitor) with a monoclonal antibody–like profile, placing Vera's lead program under Monoclonal Antibody Therapeutics.
|
$3.14B |
$49.25
-1.10%
|
|
TVTX
Travere Therapeutics, Inc.
Lead product FILSPARI (sparsentan) is an oral small molecule therapeutic for IgA nephropathy, representing the core commercial and product-focused program.
|
$3.10B |
$34.77
-0.19%
|
|
KNSA
Kiniksa Pharmaceuticals, Ltd.
Kiniksa's core clinical focus centers on immunology therapeutics, driven by ARCALYST and its inflammatory disease pipeline.
|
$3.08B |
$41.58
-0.02%
|
|
PBH
Prestige Consumer Healthcare Inc.
Clear Eyes is an ophthalmic over-the-counter product, fitting Ophthalmic Drugs.
|
$3.04B |
$61.76
+0.52%
|
|
CGON
CG Oncology, Inc. Common stock
CG Oncology is a biotech company focused on oncology therapies, with cretostimogene grenadenorepvec representing an oncology product in late-stage development.
|
$3.03B |
$39.70
-3.03%
|
|
CPRX
Catalyst Pharmaceuticals, Inc.
CPRX directly develops and sells oral small molecule therapeutics (FIRDAPSE, AGAMREE, FYCOMPA).
|
$2.96B |
$24.17
+2.33%
|
|
LQDA
Liquidia Corporation
Liquidia's YUTREPIA is a PRINT-enabled inhaled treprostinil, a drug-delivery platform that enables high-dose, deep-lung delivery and differentiated pharmacokinetics.
|
$2.94B |
$34.13
+2.25%
|
|
IDYA
IDEAYA Biosciences, Inc.
IDEAYA is a biotechnology company focused on precision oncology therapies (synthetic lethality and ADCs).
|
$2.92B |
$33.38
-1.88%
|
|
NUVB
Nuvation Bio Inc.
Core oncology focus with IBTROZI and safusidenib as oncology therapies, fitting Biotech - Oncology.
|
$2.91B |
$8.52
+1.01%
|
Showing page 5 of 25 (2438 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
